Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | LOX | P28300 | 3/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921597 | 0.80 | ESR1 (0.58) | ALDH1A1LOXHRH3MEN1KMT2A | |
| SCHEMBL56319 | 0.80 | LOX (0.57) | ALDH1A1LOXHRH3MEN1KMT2A | |
| SCHEMBL13604236 | 0.79 | KMT2A (0.71) | ALDH1A1LOXLTA4HMEN1KMT2A | |
| SCHEMBL2922255 | 0.78 | ESR1 (0.56) | ALDH1A1LOXLTA4HMEN1KMT2A | |
| SCHEMBL14476103 | 0.77 | MEN1 (0.73) | ALDH1A1LOXLTA4HMEN1KMT2A | |
| SCHEMBL8423201 | 0.76 | SMN1; SMN2 (0.60) | ALDH1A1KDM4ELOXHRH3LTA4H | |
| SCHEMBL8412814 | 0.76 | ESR1 (0.52) | ALDH1A1LOXMEN1KMT2APOLB | |
| SCHEMBL6469273 | 0.76 | HRH3 (0.52) | LOXHRH3LTA4HMEN1KMT2A | |
| SCHEMBL10720394 | 0.75 | POLB (0.51) | ALDH1A1LOXMEN1KMT2AKCNH2 | |
| SCHEMBL12015819 | 0.74 | LOX (0.51) | ALDH1A1LOXMEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6759511-B2 | A CARBONIC ACID 4-NITRO-PHENYL ESTER 2-(4-TRIFLULOROMETHYL-PHENYLSULFANYL)-ETHYL ESTER AS CHEMICAL INTERMEDIATES; AMIDATION, CARBOXYLATION, SULFONATION | HANCHEM CO., LTD. (KR) | 2004-07-06 | — | — | US | disclosed |
| US-20030220469-A1 | Novel compound used as an amino-protecting group, process for preparing the same, and synthetic method of a peptide using the same | HANCHEM CO., LTD. (KR) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220469-A1 | Novel compound used as an amino-protecting group, process for preparing the same, and synthetic method of a peptide using the same | NGLY1, VIP, BCAT2 | ALDH1A1 3147/4885KDM4E 3394/4885EPHX2 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.